Prostacyclin receptor Inhibitors
1 drugsAbout Prostacyclin receptor
The Prostacyclin receptor (IP receptor) is a G protein-coupled receptor crucial in cardiovascular physiology. It mediates vasodilation and inhibits platelet aggregation upon activation by prostacyclin.
The Prostacyclin receptor is a therapeutic target in cardiovascular disease, particularly pulmonary hypertension. Currently, there is no genetic evidence available linking the Prostacyclin receptor to specific diseases.
UPTRAVI is the only FDA-approved drug targeting the Prostacyclin receptor, developed by Actelion as a small molecule for cardiovascular indications.
Top Prostacyclin receptor Drugs
Actelion is the only company with an approved drug for this target.
High market concentration indicates potential entry barriers for new competitors.
Prostacyclin receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Prostacyclin receptor, using small molecule modality.
The lack of modality diversity represents a whitespace opportunity for novel biologics.
Prostacyclin receptor Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Prostacyclin receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 10 | 0 | 0 | 100% |
| Phase 2 | 3 | 1 | 1 | 1 | 50% |
| Phase 3 | 8 | 5 | 1 | 2 | 83% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Prostacyclin receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Prostacyclin receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Prostacyclin receptor Drug Approval Timeline (2015 - 2015)
The first and only drug, UPTRAVI, was approved in 2015.
The single approval suggests a potentially saturated market or limited druggability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Prostacyclin receptor. A trial counts if an approved drug acting on Prostacyclin receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.